GLP-1 Agonists in Serious Mental Illness: Current Evidence

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P.

Host: Richard Seeber, M.D.

Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?